Alerts will be sent to your verified email
Verify Email
CONCORD
|
Concord Drugs
|
Krebs Biochem.&Inds
|
Guj. Inject (Kerala)
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
2.78 % | 37.05 % | 2.58 % |
|
5yr average Equity Multiplier
|
1.87 | -2.13 | 0.11 |
|
5yr Average Asset Turnover Ratio
|
0.84 | 0.3 | 0.45 |
|
5yr Avg Net Profit Margin
|
1.59 % | -55.19 % | -175.28 % |
|
Price to Book
|
2.93 | 0.0 | 10.14 |
|
P/E
|
178.7 | 0.0 | 410.29 |
|
5yr Avg Cash Conversion Cycle
|
233.27 Days | -1144.52 Days | -14.62 Days |
|
Inventory Days
|
152.22 Days | 102.59 Days | 38.61 Days |
|
Days Receivable
|
106.22 Days | 8.23 Days | 0.0 |
|
Days Payable
|
74.71 Days | 623.06 Days | 156.02 Days |
|
5yr Average Interest Coverage Ratio
|
1.69 | -4.97 | 298.1 |
|
5yr Avg ROCE
|
8.41 % | -23.43 % | 2.0 % |
|
5yr Avg Operating Profit Margin
|
9.1 % | -34.39 % | -279.73 % |
|
5 yr average Debt to Equity
|
0.55 | -1.88 | -0.62 |
|
5yr CAGR Net Profit
|
-26.55 % | -0.84 % | n/a |
|
5yr Average Return on Assets
|
1.46 % | -16.47 % | -116.01 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
54.39 % | 72.74 % | 0.0 |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
5.39 % | 0.02 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Concord Drugs
|
Krebs Biochem.&Inds
|
Guj. Inject (Kerala)
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|